TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

• Ulf Mueller-Ladner,
• Hendrik Schulze-Koops,
• Tim Schmeiser,
• Hanns-Martin Lorenz,
• Christof Specker,
• Reinhard E Voll,
• Bimba F Hoyer,
• Jutta Richter,
• Alexander Pfeil,
• Rebecca Hasseli,
• Andreas Krause,
• Anne Constanze Regierer,
• Martin Schäfer

Affiliations

Ulf Mueller-Ladner

Rheumatology and Clinical Immunology, Giessen University, Bad Nauheim, Germany

Hendrik Schulze-Koops

Division of Rheumatology and Clinical Immunology, Internal Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany

Tim Schmeiser

Krankenhaus St. Josef, Wuppertal, Germany

Hanns-Martin Lorenz

Medicine V, University of Heidelberg, Heidelberg, Germany

Christof Specker

Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, Germany

Reinhard E Voll

Department of Rheumatology and Clinical Immunology, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Bimba F Hoyer

Department for Rheumatology and Clinical Immunology, University of Schleswig-Holstein at Kiel, Kiel, Germany

Jutta Richter

Policlinic for Rheumatology and Hiller Research Unit for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

Alexander Pfeil

IDIR, University of Jena, Jena, Germany

Rebecca Hasseli

Department of Rheumatology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany

Andreas Krause

Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany

Anne Constanze Regierer

Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany

Martin Schäfer

Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany